Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study

被引：0
|
作者：
Hauser, R.
Barkay, H.
Fernandez, H.
Factor, S.
Jimenez-Shahed, J.
Gross, N.
Gordon, M.
Savola, J. M.
Anderson, K.
机构：
来源：
MOVEMENT DISORDERS | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1457
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [1] Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study
    Hauser, Robert A.
    Fernandez, Hubert H.
    Stamler, David
    Davis, Mat D.
    Factor, Stewart A.
    Jimenez-Shahed, Joohi
    Ondo, William G.
    Jarskog, L. Fredrik
    Woods, Scott W.
    LeDoux, Mark S.
    Shprecher, David R.
    Anderson, Karen E.
    [J]. NEUROLOGY, 2018, 90
  • [2] Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study
    Hauser, Robert
    Barkay, Hadas
    Fernandez, Hubert
    Factor, Stewart
    Jimenez-Shahed, Joohi
    Gross, Nicholas
    Savola, Juha-Matti
    Anderson, Karen E.
    [J]. NEUROLOGY, 2019, 92 (15)
  • [3] Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study
    Anderson, K.
    Stamler, D.
    Davis, M.
    Factor, S.
    Hauser, R.
    Isojarvi, J.
    Jarskog, L.
    Jimenez-Shahed, J.
    Kumar, R.
    Ochudlo, S.
    Ondo, W.
    Fernandez, H.
    [J]. MOVEMENT DISORDERS, 2017, 32
  • [4] Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
    Hauser, R.
    Barkay, H.
    Fernandez, H.
    Factor, S.
    Jimenez-Shahed, J.
    Gross, N.
    Marinelli, L.
    Wilhelm, A.
    Gordon, M.
    Savola, J. M.
    Anderson, K.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S32 - S32
  • [5] Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study
    Hauser, Robert A.
    Barkay, Hadas
    Fernandez, Hubert H.
    Factor, Stewart A.
    Jimenez-Shahed, Joohi
    Gross, Nicholas
    Marinelli, Leslie
    Wilhelm, Amanda
    Alexander, Jessica
    Gordon, Mark Forrest
    Savola, Juha-Matti
    Anderson, Karen E.
    [J]. FRONTIERS IN NEUROLOGY, 2022, 13
  • [6] A long-term, open-label study of valbenazine for tardive dyskinesia
    Lindenmayer, Jean-Pierre
    Verghese, Cherian
    Marder, Stephen R.
    Burke, Joshua
    Jimenez, Roland
    Siegert, Scott
    Liang, Grace S.
    O'Brien, Christopher F.
    [J]. CNS SPECTRUMS, 2021, 26 (04) : 345 - 353
  • [7] Global Improvement and Patient Satisfaction: Results from a Long-Term, Open-Label, Rollover Study of Valbenazine in Tardive Dyskinesia
    Lessig, S.
    Marder, S.
    Verghese, C.
    Burke, J.
    Jimenez, R.
    Siegert, S.
    Liang, G.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S40 - S40
  • [8] Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study
    Fernandez, Hubert H.
    Stamler, David
    Davis, Mat D.
    Factor, Stewart A.
    Hauser, Robert A.
    Jimenez-Shahed, Joohi
    Ondo, William G.
    Jarskog, L. Fredrik
    Woods, Scott W.
    LeDoux, Mark S.
    Shprecher, David R.
    Anderson, Karen E.
    [J]. NEUROLOGY, 2018, 90
  • [9] Effects of long-term valbenazine in patients with tardive dyskinesia and a primary mood disorder: Results from an open-label, rollover study
    McIntyre, Roger
    Marder, Stephen
    Verghese, Cherian
    Shah, Chirag
    Farahmand, Khodayar
    [J]. BIPOLAR DISORDERS, 2020, 22 : 109 - 109
  • [10] LONG-TERM EFFECTS OF VALBENAZINE ON TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA/SCHIZOAFFECTIVE DISORDER: RESULTS FROM AN OPEN-LABEL, ROLLOVER STUDY
    Kane, John
    Marder, Stephen
    Lindenmayer, Jean-Pierre
    Jimenez, Roland
    Farahmand, Khodayar
    Siegert, Scott
    [J]. SCHIZOPHRENIA BULLETIN, 2019, 45 : S199 - S200
12345